114 related articles for article (PubMed ID: 22924678)
1. Stoppers and non-starters of disease-modifying treatment in multiple sclerosis.
Grytten N; Aarseth JH; Espeset K; Johnsen GB; Wehus R; Lund C; Haugstad RC
Acta Neurol Scand; 2013 Feb; 127(2):133-40. PubMed ID: 22924678
[TBL] [Abstract][Full Text] [Related]
2. Treatment patterns in disease-modifying therapy for patients with multiple sclerosis in the United States.
Bonafede MM; Johnson BH; Wenten M; Watson C
Clin Ther; 2013 Oct; 35(10):1501-12. PubMed ID: 24139422
[TBL] [Abstract][Full Text] [Related]
3. Health-related quality of life and disease-modifying treatment behaviour in relapsing-remitting multiple sclerosis--a multicentre cohort study.
Grytten N; Aarseth JH; Espeset K; Berg Johnsen G; Wehus R; Lund C; Riise T; Haugstad R
Acta Neurol Scand Suppl; 2012; (195):51-7. PubMed ID: 23278657
[TBL] [Abstract][Full Text] [Related]
4. Accounting for disease modifying therapy in models of clinical progression in multiple sclerosis.
Healy BC; Engler D; Gholipour T; Weiner H; Bakshi R; Chitnis T
J Neurol Sci; 2011 Apr; 303(1-2):109-13. PubMed ID: 21251671
[TBL] [Abstract][Full Text] [Related]
5. Switching first-line disease-modifying therapy after failure: impact on the course of relapsing-remitting multiple sclerosis.
Gajofatto A; Bacchetti P; Grimes B; High A; Waubant E
Mult Scler; 2009 Jan; 15(1):50-8. PubMed ID: 18922831
[TBL] [Abstract][Full Text] [Related]
6. Clinical follow-up of 304 patients with multiple sclerosis three years after mitoxantrone treatment.
Debouverie M; Taillandier L; Pittion-Vouyovitch S; Louis S; Vespignani H
Mult Scler; 2007 Jun; 13(5):626-31. PubMed ID: 17548442
[TBL] [Abstract][Full Text] [Related]
7. Medication adherence with disease modifying treatments for multiple sclerosis among US employees.
Kleinman NL; Beren IA; Rajagopalan K; Brook RA
J Med Econ; 2010; 13(4):633-40. PubMed ID: 20958113
[TBL] [Abstract][Full Text] [Related]
8. Reasons patients give to use or not to use immunomodulating agents for multiple sclerosis.
Visser LH; van der Zande A
Eur J Neurol; 2011 Nov; 18(11):1343-9. PubMed ID: 21496180
[TBL] [Abstract][Full Text] [Related]
9. Effects of glatiramer acetate on spasticity in previously interferon-beta-treated and treatment-naive patients with relapsing-remitting multiple sclerosis: a prospective, nonrandomized, open-label, uncontrolled, observational pilot study.
Meca-Lallana JE; de Mingo-Casado P; Amorin-Díaz M; Martínez-Navarro ML; Barreiro AF
Clin Ther; 2010 Jun; 32(6):1061-6. PubMed ID: 20637960
[TBL] [Abstract][Full Text] [Related]
10. Non-adherence to interferon-beta therapy in Swedish patients with multiple sclerosis.
Cunningham A; Gottberg K; von Koch L; Hillert J
Acta Neurol Scand; 2010 Mar; 121(3):154-60. PubMed ID: 20055771
[TBL] [Abstract][Full Text] [Related]
11. Characteristics influencing therapy switch behavior after suboptimal response to first-line treatment in patients with multiple sclerosis.
Teter B; Agashivala N; Kavak K; Chouhfeh L; Hashmonay R; Weinstock-Guttman B
Mult Scler; 2014 Jun; 20(7):830-6. PubMed ID: 24277325
[TBL] [Abstract][Full Text] [Related]
12. [Glatiramer acetate in interferon beta non respondent relapsing-remitting multiple sclerosis].
Oreja-Guevara C; Bermejo PE; Miralles A; Gabaldón L; Aguilar MJ; Díez-Tejedor E
Neurologia; 2009 Sep; 24(7):435-8. PubMed ID: 19921551
[TBL] [Abstract][Full Text] [Related]
13. [Global adherence project to disease-modifying therapies in patients with relapsing multiple sclerosis: 2-year interim results].
Arroyo E; Grau C; Ramo C; Parra J; Sánchez-Soliño O;
Neurologia; 2010 Sep; 25(7):435-42. PubMed ID: 20964990
[TBL] [Abstract][Full Text] [Related]
14. Effect of disease-modifying therapies on brain volume in relapsing-remitting multiple sclerosis: results of a five-year brain MRI study.
Khan O; Bao F; Shah M; Caon C; Tselis A; Bailey R; Silverman B; Zak I
J Neurol Sci; 2012 Jan; 312(1-2):7-12. PubMed ID: 21920559
[TBL] [Abstract][Full Text] [Related]
15. Discontinuing disease-modifying therapy in MS after a prolonged relapse-free period: a propensity score-matched study.
Kister I; Spelman T; Alroughani R; Lechner-Scott J; Duquette P; Grand'Maison F; Slee M; Lugaresi A; Barnett M; Grammond P; Iuliano G; Hupperts R; Pucci E; Trojano M; Butzkueven H;
J Neurol Neurosurg Psychiatry; 2016 Oct; 87(10):1133-7. PubMed ID: 27298148
[TBL] [Abstract][Full Text] [Related]
16. Medication adherence to disease-modifying therapies among a cohort of Jordanian patients with relapsing-remitting multiple sclerosis: a multicentre cross-sectional study.
Al-Keilani MS; Almomani BA
Int J Pharm Pract; 2023 Apr; 31(2):198-205. PubMed ID: 36738264
[TBL] [Abstract][Full Text] [Related]
17. Real-world persistence of multiple sclerosis disease-modifying therapies.
Tallantyre EC; Dobson R; Froud JLJ; St John FA; Anderson VM; Arun T; Buckley L; Evangelou N; Ford HL; Galea I; George S; Gray OM; Hibbert AM; Hu M; Hughes SE; Ingram G; Kalra S; Lim CE; Mathews JTM; McDonnell GV; Mescall N; Norris S; Ramsay SJ; Rice CM; Russell MJ; Shawe-Taylor MJ; Williams TE; Harding KE; Robertson NP
Eur J Neurol; 2024 Jul; 31(7):e16289. PubMed ID: 38567516
[TBL] [Abstract][Full Text] [Related]
18. Impact of disease-modifying treatments in North African migrants with multiple sclerosis in France.
Lebrun C; Debouverie M; Jeannin S; Pittion-Vouyovitch S; Bayreuther C; Berthier F
Mult Scler; 2008 Aug; 14(7):933-9. PubMed ID: 18573824
[TBL] [Abstract][Full Text] [Related]
19. The Impact of Patient Support Programs on Adherence to Disease-Modifying Therapies of Patients with Relapsing-Remitting Multiple Sclerosis in Germany: A Non-Interventional, Prospective Study.
Lenz F; Harms L
Adv Ther; 2020 Jun; 37(6):2999-3009. PubMed ID: 32333326
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of early initiation of fingolimod versus delayed initiation after 1 year of intramuscular interferon beta-1a in patients with multiple sclerosis.
Agashivala N; Kim E
Clin Ther; 2012 Jul; 34(7):1583-90. PubMed ID: 22749258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
